Lead Product(s) : Zibotentan,Dapagliflozin
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Zibotentan/dapagliflozin combination leverages SGLT2 inhibition and high selectivity ETA receptor antagonism. It is being evaluated in phase 2 clinical trials for the treatment of chronic kidney disease and proteinuria.
Brand Name : ZD4054
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 03, 2023
Lead Product(s) : Zibotentan,Dapagliflozin
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?